Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Wuhan Kindstar Diagnostics In-licenses Epigenomics’ Lung Cancer Test

publication date: Jan 13, 2014
Wuhan Kindstar Clinical Diagnostics, China’s largest provider of esoteric diagnostic testing services, in-licensed a lung cancer test from Germany’s Epigenomics. Epi proLung® is a tissue assay that has been approved for use in Europe. Epigenomics will supply the product to Kindstar and also provide support for approval. Financial terms of the agreement were not disclosed. More details....

Stock Symbols: (F: ECX, OTC: EPGNY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital